tafasitamab sold brand name monjuvi medication used combination lenalidomide treatment adults relapsed refractory diffuse large bcell lymphoma tafasitamab may cause serious side effects including infusion related reactions bone marrow suppression infections harm unborn common side effects tafasitamab low blood cell counts fatigue diarrhea cough fever limb swelling upper respiratory infection decreased tafasitamab humanized fcmodified cytolytic tafasitamab approved medical use united states july european union august us food drug administration fda considers firstinclass tafasitamab combination lenalidomide indicated treatment adults relapsed refractory diffuse large bcell lymphoma eu minjuvi indicated combination lenalidomide followed tafasitamab monotherapy treatment adults relapsed refractory diffuse large bcell lymphoma eligible autologous stem cell fda approved tafasitamab based primarily evidence one clinical trial participants years participants trial lymphoma relapsed improve prior trial conducted sites united states first participants received tafasitamab combination lenalidomide later tafasitamab alone following specific schedule treatment treatment continued disease progression unacceptable side participants health care providers knew treatment benefit tafasitamab evaluated measuring many participants complete partial tumor shrinkage long response lasted called best overall response tafasitamab international nonproprietary name monoclonal article stub help wikipedia expanding antineoplastic immunomodulatory drug article stub help wikipedia expanding httpsenwikipediaorgwikitafasitamab